Drug Safety-related Labeling Changes (SrLC)

Get Email Alerts | Guide

Drug Safety-related Labeling Changes (SrLC) Database

ANDA	Abbreviated New Drug Application
BLA	Biologics License Application
CDER	Center for Drug Evaluation and Research
MG	Medication Guide
NDA	New Drug Application
PCI	Patient Counseling Information
PI	Patient Information
PLR	Physician Labeling Rule
PLLR	Pregnancy and Lactation Labeling Rule
Italics	For the most part, italics indicate an FDA comment such as: Additions and/or revisions underlined These italics usually appear at the beginning of the section. In some cases, italics may be an inherent part of the label, and will most often appear in the body of the section.
Underlines	Any text that is underlined indicates text that has been added or revised. There are exceptions where underlining occurs in a section subtitle or heading. This is the case when there is just one word underlined in the body of the text.

Sections

BW	Box Warning
WP	Warnings and Precautions all in one section (PLR-format) Warnings as one section (pre-PLR format) Precautions as one section (pre-PLR format)
AR	Adverse Reactions (in pre-PLR format, this may be a subheading under precautions).
DI	Drug Interactions (in pre-PLR format, this may be a subheading under precautions).
USP	Use in Specific Populations (Inclusive on one or more of the following: Pregnancy; Lactation (PLLR- format); Nursing Mothers (pre-PLLR format); Females and Males of Reproductive Potential (PLLR format only); Pediatric Use, Geriatric Use, Renal Impairment, Hepatic Impairment, Sex, Race (these last six may be a subheading of precautions if label in pre-PLLR format.
PCI/PI/MG	Patient Counseling Information (PLR format only) - summarizes the information that a health care provider should convey to a patient (or caregiver when applicable) when a counseling discussion is taking place (e.g., a physician prescribing a drug during an office visit, a nurse providing discharge instructions at a hospital, or a pharmacist conveying information at a pharmacy). Patient Information - FDA approved patient labeling. Medication Guide - paper handouts that come with many prescription medicines. The guides address issues that are specific to particular drugs and drug classes, and they contain FDA-approved information that can help patients avoid serious adverse events.

Only NDAs and CDER regulated BLAs are included in this database. ANDAs are not included.

Applications that remain active, even if the product has been discontinued, undergo safety-related labeling changes.

VIGAFYDE (NDA-217684)

(VIGABATRIN)

Safety-related Labeling Changes Approved by FDA Center for Drug Evaluation and Research (CDER)

Download Data

Expand all

09/03/2025 (SUPPL-2)

Approved Drug Label (PDF)

5 Warnings and Precautions

5.2 Vigabatrin REMS

Additions and/or revisions underlined:

VIGAFYDE is available only through a restricted distribution program called the Vigabatrin REMS, because of the risk of permanent vision loss.

Notable requirements of the Vigabatrin REMS include the following:

Prescribers must be certified by enrolling in the program, agreeing to counsel caregivers on the risk of vision loss and the need for periodic monitoring of vision, and reporting any event suggestive of vision loss to the REMS program.

…

5.4 Neurotoxicity

Additions and/or revisions underlined:

…

In a published study, vigabatrin (200, 400 mg/kg/day) induced apoptotic neurodegeneration in the brain of young rats when administered by intraperitoneal injection on postnatal days 5-7.

17 PCI/PI/MG (Patient Counseling Information/Patient Information/Medication Guide)

PATIENT COUNSELING INFORMATION

Additions and/or revisions underlined:

…

Instruct caregivers that VIGAFYDE should not be diluted prior to dosing.

Advise the caregiver that VIGAFYDE may be given orally or via gastrostomy (G) tube. Doses administered via gastrojejunal (GJ) tubes must be administered through the G-port. If VIGAFYDE will be administered via G-tube, provide instructions to the caregiver(s) as to how to flush the tube after administration.

…

MEDICATION GUIDE

Additions and/or revisions underlined:

How should my baby take VIGAFYDE?

…

VIGAFYDE may be given by mouth or given through a gastrostomy (G) tube. If VIGAFYDE is given through a gastrojejunal (GJ) tube, the Gport must be used. Give the medicine as directed by your baby’s healthcare provider, and flush the tube after administration with the amount of water recommended by your healthcare provider.

09/03/2025 (SUPPL-4)

Approved Drug Label (PDF)

5 Warnings and Precautions

5.2 Vigabatrin REMS

Additions and/or revisions underlined:

VIGAFYDE is available only through a restricted distribution program called the Vigabatrin REMS, because of the risk of permanent vision loss.

Notable requirements of the Vigabatrin REMS include the following:

Prescribers must be certified by enrolling in the program, agreeing to counsel caregivers on the risk of vision loss and the need for periodic monitoring of vision, and reporting any event suggestive of vision loss to the REMS program.

…

5.4 Neurotoxicity

Additions and/or revisions underlined:

…

In a published study, vigabatrin (200, 400 mg/kg/day) induced apoptotic neurodegeneration in the brain of young rats when administered by intraperitoneal injection on postnatal days 5-7.

17 PCI/PI/MG (Patient Counseling Information/Patient Information/Medication Guide)

PATIENT COUNSELING INFORMATION

Additions and/or revisions underlined:

…

Instruct caregivers that VIGAFYDE should not be diluted prior to dosing.

…

MEDICATION GUIDE

Additions and/or revisions underlined:

How should my baby take VIGAFYDE?

…

VIGAFYDE may be given by mouth or given through a gastrostomy (G) tube. If VIGAFYDE is given through a gastrojejunal (GJ) tube, the Gport must be used. Give the medicine as directed by your baby’s healthcare provider, and flush the tube after administration with the amount of water recommended by your healthcare provider.